Please use this identifier to cite or link to this item:
Title: Breakthrough cancer pain - still a challenge.
Authors: Margarit, Cesar
López, Rafael
Anton, Antonio
Escobar, Yolanda
Casas, Ana
Cruz, Juan Jesús
Galvez, Rafael
Mañas, Ana
Zaragozá, Francisco
metadata.dc.contributor.authoraffiliation: [Margarit,C] Pain Unit, Alicante University General Hospital, Alicante, Spain. [Juliá,J] Department of Integral Support-Palliative Care, Catalan Institute of Oncology (ICO), Germans Trias i Pujol University Hospital, Badalona, Spain. [López,R] Department of Clinical Oncology, University Hospital Complex, Santiago de Compostela, Spain. [Anton,A] Department of Clinical Oncology, Miguel Servet Hospital, Zaragoza, Spain. [Escobar,Y] Department of Clinical Oncology, Gregorio Marañón Hospital, Madrid, Spain. [Casas,A] Department of Oncology, Virgen Macarena Hospital, Seville, Spain. [Cruz,JJ] Department of Clinical Oncology, Salamanca Hospital, Salamanca, Spain. [Galvez,R] Pain and Palliative Care Unit, Virgen de las Nieves Hospital, Granada, Spain. [Mañas,A] Department of Oncology–Radiotherapy, La Paz Hospital, Madrid, Spain. [Zaragozá,F] Department of Pharmacology, University of Alcalá de Henares, Spain.
Keywords: Prevalence;Management;Diagnosis;Opioids;Prevalencia;Diagnóstico;Analgésicos Opioides;Fentanilo;Pectinas;Dolor intercurrente
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Pain::Breakthrough Pain
Medical Subject Headings::Health Care
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Sensory System Agents::Analgesics::Analgesics, Opioid
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Piperidines::Fentanyl
Medical Subject Headings::Chemicals and Drugs::Macromolecular Substances::Polymers::Biopolymers::Pectins
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis
Issue Date: 19-Nov-2012
Publisher: Dove Medical Press
Citation: Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, et al. Breakthrough cancer pain - still a challenge. J Pain Res. 2012, 5:559-66
Abstract: Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%). According to the American Pain Foundation, breakthrough pain is observed in 50%-90% of all hospitalized cancer patients, in 89% of all patients admitted to homes for the elderly and terminal-patient care centers, and in 35% of all ambulatory care cancer patients. The management of breakthrough cancer pain should involve an interdisciplinary and multimodal approach. The introduction of new fentanyl formulations has represented a great advance and has notably improved treatment. Among these, the pectin-based intranasal formulation adjusts very well to the profile of breakthrough pain attacks, is effective, has a good toxicity profile, and allows for convenient dosing - affording rapid and effective analgesia with the added advantage of being easily administered by caregivers when patients are unable to collaborate.
Description: Journal Article;
metadata.dc.identifier.doi: 10.2147/JPR.S36428
ISSN: 1178-7090 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de las Nieves
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
MargaritC_Breakthrough cancer pain.pdfReview224,95 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons